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Background: Carcinosarcoma is a malignancy that rarely occurs in the renal pelvis.
Materials and methods: We present a case of histologically proven, native renal pelvis carcinosarcoma in a 65-year-old
woman who had accepted a renal transplant. We performed a laparoscopic ureterectomy, combined with
lymph node dissection and immunosuppression with sirolimus (SRL), which was alternated with the conventional
immunosuppressant - cyclosporine.
Results: This patient was still alive 34 months after renal transplantation.
Conclusions: Operation is still the best choice, and the SRL may be beneficial for preventing the progression of a tumor.
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The overall incidence of de novo malignancies in renal
transplant (RT) recipients is significantly higher than in
the general population due to long-term immunosuppres-
sive therapy and oncogenic viral infections [1,2]. The
malignant tumors of the transplanted kidney are mainly
nonmelanoma skin cancers and malignancies, including
post-transplant lymphoproliferative disorder and solid
organ cancer [3,4]. The prevalence and characteristics of
post-transplant malignancies differ in various geographic
areas. In western countries, the most common type of
post-transplant urinary tract malignancy is renal cell
carcinoma [1]. In contrast, the majority of reported tu-
mors in Chinese patients were urothelial carcinomas
[5,6], which occurred in 4.1% of all RT recipients and
47.6% of all patients with a post-transplant malignancy
[6]. Carcinosarcoma of the kidney and renal pelvis
(CSKP) commonly presented as high-grade, advanced
stage disease, and was associated with a poor prognosis
regardless of location [7].
Carcinosarcoma of the renal pelvis is an extremely rare
malignancy with a poor prognosis in the few reported* Correspondence: LiCaicailicl@163.com; ZhenliGaogzl@163.com
†Equal contributors
2Department of Pathology, Yantai Yuhuangding Hospital, No.20 East
Yuhuangding Road, Yantai, Shandong Province 264000, China
1Department of Urology, Yantai Yuhuangding Hospital, No.20 East
Yuhuangding Road, Yantai, Shandong Province 264000, China
© 2014 Wu et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cases [8-11]. The carcinosarcoma of the renal pelvis in
patients after renal transplantation is rarer. Here, we
present a histologically proven case of carcinosarcoma of
the left renal pelvis in renal transplant recipient.Case presentation
A 65-year-old female patient developed chronic renal failure
with unknown etiology and began hemodialysis in 2003.
The patient denied past tobacco use or analgesic abuse.
The patient received a renal transplantation in 2005 from
a male cadaveric donor. Immunosuppressive therapy was
applied using a triple immunosuppressive regimen, in-
cluding cyclosporine (CsA), prednisone, and mycophenolate
mofetil.
The patient suffered from a pulmonary cytomegalovirus
infection 8 months after the renal transplantation, and
took oral cyclosporine and prednisone for a combination
immunosuppressive treatment after the transplant. She
had normal renal function, and the serum creatinine levels
were maintained at 0.62 to 0.88 mg/dL. Forty-eight months
after the renal transplantation, the patient went to the local
hospital because of recurrent gross hematuria with waist
pain on the left side. The CT examination revealed a left
pelvic lesion of approximately 5 cm × 4 cm (Figure 1). It
was showed in the CT image that, irregular nodular soft
tissue shadow filled in the left pelvis; the adjacent calyces
and renal parenchyma were compressed; and there was nois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Computed tomography (CT) scan revealed a 5 cm× 4 cm
lesion in the left pelvic region.
Figure 2 Pathological examination of the lesion.
Figure 3 Immunohistochemical examination of the cytokeratin.
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copy and chest computed tomography (CT) examinations
revealed no abnormalities.
A pathological examination showed that the size of the
full-cut kidney and the surrounding fat capsule was
15 cm × 10 cm × 5 cm, and the actual kidney size was
12 cm × 7 cm × 4 cm. A bulging mass of 6 cm × 4 cm
was observed at the renal pelvic cut surface without an
envelope. This mass showed infiltrative growth that was
gray and of fine quality, partly translucent and jelly-like,
and also showed some hemorrhagic and necrotic areas.
The renal parenchyma was atrophied and the ureteral
length was 8 cm. Microscopic observations revealed two
tumor components. One was a high-grade urothelial
carcinoma component with partial papillary arrangement,
and the epithelial cells were mostly heterotypic and pleo-
morphic, with some of them falling off. The cell nucleus
was obviously pleomorphic, deeply stained, and the nucle-
olus was prominent and visible with pathological mitotic
figures. The other was a heterologous sarcomatous com-
ponent with a malignant peripheral nerve sheath tumor
(MPNST) structure, and this was the dominant compo-
nent. The tumors showed a diffuse growth or formed
an alternate distribution of cell-rich areas and cell-sparse
areas. The sparse areas were associated with myxoid
stroma. The blood vessels were surrounded by tumor
cells. The cells were fusiform and polygonal, and the
cytoplasm was abundant, with red staining. The nucleus
was large, deeply stained and irregular, and the nucleolus
was prominent, with visible mitotic figures, multifocal
necrosis and hemorrhage. Part of the region showed
urothelial carcinoma and MPNST component with a
transitional phase (Figure 2). According to the TNMclassification system, the patient was diagnosed with
stage pT3N0M0.
An immunohistochemical examination showed that cyto-
keratin of the urothelial carcinoma was positive (Figure 3).
Vimentin was positive in the sarcoma, and was negative in
the urothelial carcinoma (Figure 4). Some of the MPNST
cells S-100 were positive in the carcinoma and sarcoma
transition area, and strongly positive in the area of the
sarcoma cells (Figure 5). Smooth muscle actin (SMA) of
sarcoma cells was negative, and Human Melanoma Black
(HMB45) and desmin were negative.
The pathological diagnosis was that the left renal pelvic
carcinosarcoma invaded the renal parenchyma, but was
not involved the ureteral stump.
The patient accepted laparoscopic ureterectomy com-
bined with lymph node dissection in our hospital. The op-
eration went well, and 7 days after the operation, she was
discharged from the hospital as she had recuperated. One
week after the operation, she began to adjust the immuno-
suppressive regimen by using sirolimus (SRL) instead of
Figure 4 Immunohistochemical examination of the vimentin.
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and 1 mg the next day, which was taken 4 hours after
meals. Regular monitoring of blood concentrations was
carried out after the conversion, and the drug dosage
was adjusted according to the blood concentration, to
maintain a plasma concentration of 4 to 6 μg/L of SRL.
The patient refused to undergo any adjuvant therapy
after the operation. She accepted regular postoperative
follow-up. At the time of writing, 34 months after the
left kidney ureterectomy, she is still alive with normal
renal function.
Discussion
The overall incidence of de novo malignancies after RT
is four to five times higher than that in the general popula-
tion and has been estimated to be as high as 20% after
10 years [1]. According to the Cincinnati Transplant
Tumor Registry, the most prevalent de novo neoplasms
in organ transplant recipients are skin cancers and post-
transplant lymphoproliferative disease [1,2]. For urinaryFigure 5 Immunohistochemical examination of S-100.tract, renal cell carcinoma (RCC) was the most frequent
tumor after RT in the west [1,5], with urothelium can-
cer being most frequent in China [6]. The development
of carcinosarcoma is well documented in the mammary
gland, the larynx and the uterus. Less frequently, de-
velopment in bladder, esophageal, lung and kidney has
been reported. Fewer than twenty cases of carcinosarcoma
of the pelvis have been described in the literature.
Carcinosarcoma is often difficult to distinguish from
sarcomatoid carcinoma. Carcinosarcomas are composed
of epithelial and sarcomatous components, and sarcomatoid
carcinomas are malignant spindle cell neoplasms composed
of epithelial components containing changes of sarcomatoid
morphology [12]. Microscopically, the carcinomatous com-
ponent is mostly transitional cell carcinoma and the
sarcomatous component is largely composed of spindle or
pleomorphic tumor giant-cells. Carcinosarcomas and
sarcomatoid carcinomas are similar on hematoxylineosin
staining, so immunohistochemical study is mandatory for
diagnosis. In this case, epithelial component expressed
cytokeratins while sarcomatous component vimentin and
S-100. The pathological diagnosis is confirmed.
Exact survival rate remains a matter of controversy due
to a lack of consistent long-term follow-up. Wang et al.
reviewed the carcinosarcoma involving kidney and renal
pelvis, and the median cancer specific survival was
6 months and the 1-year cancer specific survival rate
for the entire cohort was 30.2% [7]. In the present report,
this patient is still alive (>34 months) with normal renal
function and no metastasis. This survival may be because
regular follow-up allowed for diagnosis and treatment
of the tumor in an early stage and because SRL instead
of cyclosporine may have suppressed the progression of
tumor. Hojo et al. has reported that cyclosporine can
promote cancer progression by a direct cellular effect
that is independent of its effect on the host’s immune cells,
and that cyclosporine-induced transforming growth factor-
beta (TGF-beta) production is involved in this [13]. That is
to say, cyclosporine can also promote cancer progression
directly. As is reported, when compared with cyclosporine,
SRL induce adverse events more frequently, but the mean
MDRD eGFR is higher for renal function [14]. The reintro-
duction of calcineurin inhibitors is safe in patients who
have been withdrawn from sirolimus owing to adverse
effects [15]. SRL, besides its antiangiogenic properties,
has a strong tumor-specific functional effect on established
tumor vessels [16].
Carcinosarcoma is rare in renal pelvis but progresses
rapidly and has an unsatisfactory prognosis. The pathologic
stage is the main predictor of patient survival. No direct
correlation has been found with previous stone disease,
infection, or radiation exposure and tumor development.
Chemotherapy offers little response and no survival ad-
vantage [17-20]. Treatment is early nephrectomy. For this,
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kidneys should be screened for tumors by ultrasound after
transplantation [21]. Thus, tumors can be diagnosed at
an early stage. RT recipients should do ultrasound and
CT in regular postoperative follow-ups to allow for the
diagnosis of carcinosarcoma at an early stage. Nonfunc-
tioning native kidneys with suspicious lesions should be
removed early [5].
Conclusion
In conclusion, carcinosarcoma is rare in the renal pelvis,
progresses rapidly and has an unsatisfactory prognosis. It
is not sensitive to chemo-radiation. Operation is still the
best choice, and the SRL may be beneficial for preventing
the progression of the tumor. From a therapeutic and
prognostic point of view, it is important to make a correct
and early diagnosis.
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